Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces its audited results for the year ended 31 March 2022.

Click here to read the full announcement

Click here to read our unaudited interim results for the six months ended 30 September 2021

Omega announces that following completion of the of US performance studies, its technology partner, Mologic Ltd has filed its submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation for its rapid point-of-care COVID-19 antigen test, for use under both the Omega’s VISITECT^® brand and Global Access Diagnostics (GAD) brand.

Read the full RNS here

The Company remains in regular dialogue with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose.

Read the full RNS here

Omega launches our VISITECT^® COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections.

Read the full RNS here

Omega announces that it has CE-Marked Mologic Ltd’s lateral flow antigen test for COVID-19, to be sold for professional-use under Omega’s VISITECT^® brand.

Read the full RNS here

Omega's contract with DHSC to provide manufacturing capacity for COVID-19 lateral flow antigen tests estimated at £374 million.

Read the full RNS here

Omega announces that it has signed a contract with Screen4 Ltd to provide a testing service using the Mologic ELISA antibody test for COVID-19 from our in-house testing laboratory in Littleport, Cambridgeshire. This follows the launch of the COVID-19 antibody testing service, as announced on 26 January 2021.

Read the full RNS here

We are pleased to announce the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect and has also become a member of both the Audit Committee and the Remuneration Committee.

Read the full RNS here

Omega announces that it has agreed a contract with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow antigen tests, as part of the UK Government’s well-publicised target of producing two million lateral flow tests per day.

Read the full RNS here